Background: CC chemokine receptor 5 (CCR5) is a cell entry cofactor for macrophage-tropic isolates of human immunodeficiency virus-I (HIV-1). Recently, an inactive CCR5 allele (designated here as CCR5-2) was identified that confers resistance to HIV-1 infection in homozy-
INTRODUCTION
Chemokine receptors are a group of 7-transmembrane domain proteins originally studied in the context of leukocyte chemotaxis (1) . Recently, several chemokine receptors-CXCR4, CCR2B, CCR3, and CCR5 (designated according to a recent nomenclature convention)-have been shown to serve as HIV-1 cell-entry cofactors in vitro, acting in concert with CD4 and the gp120 viral envelope glycoprotein to mediate the first step in the human immunodeficiency virus-I (HIV-1) life cycle, fusion of the viral envelope with the plasma membrane (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) .
Different passaged strains of HIV-1 exhibit different chemokine receptor preferences, the result of sequence polymorphisms in gpl20. Socalled macrophage-tropic, or nonsyncytiuminducing strains, use CCR3 and CCR5 preferentially; these strains have properties similar to most primary isolates from infected individuals who have not yet progressed to AIDS (13, 14) . So-called T cell line-tropic, or syncytium-inducing strains, use CXCR4 (previously referred to as fusin, HUMSTSR, and LESTR) and CCR3 preferentially; primary isolates from patients with advanced AIDS often have properties similar to these passaged strains. CCR2B, CCR5, and CXCR4 are all expressed on macrophages and CD4+ T cells, whereas CCR3 is expressed on eosinophils (15) (16) (17) (18) (19) (20) (21) . Primary isolates have been identified that can use all four of these receptors for cell entry (4, 5, 8) .
A role for CCR5 in susceptibility to HIV-1 infection has been supported recently by three groups who independently identified a mutant allele containing a 32 base pair deletion in the open reading frame (ORF) of the CCR5 gene that induces a frame shift, a premature stop codon, and loss of HIV-1 coreceptor activity in vitro (10) (11) (12) . We will refer to the mutant allele as CCR5-2 and the wild-type allele as CCR5-1. Sixteen and one percent of healthy European Caucasians were reported to be heterozygous and homozygous for CCR5-2, respectively; however, the mutant allele was not observed in Japanese or black Africans (11, 12) . A large survey of the mutation in North Americans at risk for HIV-1 infection identified high prevalence in Caucasians and relatively low prevalence in AfricanAmericans; however, a systematic survey of the general population was not reported (12) .
CCR5-2 was found in homozygous form by Liu et al. in two individuals (EU2 and EU3) who, as they had previously reported, remain uninfected despite high exposure to HIV-1 and whose peripheral blood mononuclear cells resist infection with macrophage-tropic HIV-1 in vitro (10, 22) . In contrast, in 723 and 1,343 HIV-1+ individuals typed by Samson et al. and Dean et al., no individual homozygous for the mutant allele was identified, indicating that this genotype is a powerful restriction factor for HIV-1 transmission (1 1, 12) . Samson et al. also reported a 3 5% decrease in heterozygotes among HIV-1 + individuals relative to seronegative controls, whereas Dean et al. reported no significant difference (11, 12) . Dean et al. also reported that HIV-1+ CCR5-2 heterozygous individuals progress slightly less rapidly to AIDS compared with homozygous wild-type individuals in homosexual cohorts, but not in hemophilia cohorts (12) . The risk levels of the cohorts of exposed-uninfected individuals have not been previously correlated with the CCR5 genotype.
We have independently identified the CCR5-2 allele and studied its effects on HIV-1 susceptibility and disease progression in individuals with contrasting clinical phenotypes, defined race, and quantified risk. In addition, we report a systematic and unbiased survey of CCR5 genotypes in North American racial groups. (24) , ranged from 43 to 501 for individuals in the top tenth percentile. The second group was composed of 28 men identified as seronegative MACS participants from whom HIV-1 was isolated at least once (25) . Six of these latter individuals also had risk scores in the top tenth percentile, giving a total of 12 5 highly exposed-seronegative individuals studied (24, 25) .
MATERIAL AND METHODS

DNA Extraction
Human genomic DNA was purified from either 100 ,l whole blood or -1 million purified peripheral blood leukocytes by methods described previously (26) .
PCR Amplification PCR amplification of the CCR5 full-length open reading frame (ORF) was performed using the following two primers: CCR5-up: 5' -CCCAAGC TTACTCTCCCCGGGTGGAACAAGATG -3' and CCR5 down: 5' -GGTCTAGAGTCACCAGCCCA CTTGAGTCCGTG -3'. These same primers were utilized to amplify a CCR5-like sequence from chimpanzee DNA to be used as an outgroup heteroduplex probe, a strategy used previously to reveal human genetic polymorphisms (26, 28) . Amplification reactions were performed in a solution (100 ,ul) containing 30 Directed Heteroduplex Analysis (DHDA) DHDA was performed as described previously (28) . Briefly, 5 ,lI of the unlabeled amplicon from human genomic DNA were mixed directly with 5 pL1 of the biotin-labeled CCR5 probe amplified from chimpanzee genomic DNA using a 5'-biotinylated CCR5-up primer (Operon Technologies, Alameda, CA) and an unbiotinylated CCR5-down primer. Following a 2-min incubation at 95°C to denature the PCR products, the reactions were cooled to 40C (ramp time = 45 sec). Heteroduplex reactions (7 ,ll) were mixed with sample dye buffer (0.2 5% bromophenol blue; 0.25% xylene cyanol; 30% glycerol) and samples of 3.5 ,ll were loaded onto a 6% Genepage+ (Amresco, Solon, OH) polyacrylamide gel (2.7 M urea). Electrophoresis was performed on 50 cm sequencing gels at 40 mAmps for 2.5-3 hr in 1 X TBE. The temperature of the gel was maintained between 400 and 450C. Detection of heteroduplex products formed with the biotinylated probe was performed following "contactblot" transfer to positively charged Biodyne-B nylon membranes (ICN Biochemicals, Cleveland, OH) using the PhototopeTm detection system (New England Biolabs, Beverly, MA) as described previously (26) .
Cloning of PCR Products
Following amplification from human genomic DNA templates, PCR products showing novel heteroduplex mobility were cloned into pCR2.1 (Invitrogen, La Jolla, CA). Multiple clones from DNA derived from two North American Caucasians and two African-Americans were sequenced using both manual dideoxy-nucleotide chain termination sequencing and automated sequencing (ABI 373A, Applied Biosystems, Foster City, CA).
Detection of PCR-amplified CCR5 Alleles Following PCR amplification of genomic DNA, 5 ,ul were subjected directly to Bgl II digestion, and the products were visualized following electrophoresis on a 3% agarose gel (5:1 GTG NuSieve:LE agarose) stained with ethidium bromide. Alternatively, following PCR amplification of human genomic DNA using a 5'-unbiotinylated CCR5-up and a biotinylated CCR5-down primer pair, ELISA-based detection of CCR5 amplicons was performed as described previously (29) modified only by the use of fluoresceinated (FL) sequence-specific oligonucleotide probes. The probe names are 5.1 (5'-FL-GTATCAATTCT GGAAGAATTTCCAG-FL-3'), which is specific for CCR5-1, and 5.2 (5'-FL-CATTrTCCATACAT TAAAGGTAGTC-FL-3'), which is specific for CCR5-2. A filter mat detection system was also developed using methods identical to those described previously (30) , and probes 5.1 and 5.2 labeled with digoxigenin rather than fluorescein. (31) . The dual-tropic 89.6 Env (cloned into pSC59 vector) was expressed on HeLa cells by lipofection and infection with vCB-2 1 R. The two types of cells were incubated separately overnight at 310C to allow synthesis of vaccinia virus-encoded proteins, then washed, resuspended at 106 per ml, and cocultured in duplicate for 2.5 hr at 37°C. Samples were then analyzed by a colorimetric lysate assay for 13-galactosidase activity indicative of fusion of the T7 polymerase expressing NIH-3T3 cells with the lac Z-containing HeLa cells (3).
Statistical Analysis
The significance of differences in genotypic frequencies between different populations was tested by chi-square. The proportion of MACS seroconvertors remaining free of AIDS was computed using Kaplan-Meier estimates, and hypothesis tests of differences of survival curves were performed using Cox proportional-hazards models. The 32 nucleotide deletion is identical to the mutation previously reported (10) (11) (12) . It results in a frame shift altering the deduced wild-type sequence beyond the predicted second extracellular loop of the receptor ( Fig. 2A) , a region shown to be critical for ligand binding by chemokine receptors (33) . Moreover, it introduces a premature stop codon at nucleotide 678 of the reference sequence located in the region encoding the predicted third intracellular loop. Just upstream of the deletion resides a Bgl II site allowing for restriction fragment length polymorphism (RFLP) resolution of the wild-type and deleted sequences (Fig. 2B) . Furthermore, we have developed allele-specific oligonucleotide probes that can be used in high throughput genotypic analysis using either 96-well plates (Fig. 2B ) or filter mats (data not shown). Using these methods, we identified one individual in the group screened by heteroduplex analysis who was homozygous for the deletion, proving that the sequence containing the deletion resides at the functional locus and is not a pseudogene.
RESULTS
Discovery of a Mutant
Lack of HIV-1 Fusion-promoting Activity for CCR5-2 We next examined the HIV-1 coreceptor activity of the mutant allele, CCR5-2, using a vacciniabased cell-cell fusion system (30) . This assay models the first step in HIV-1 infection, envelope glycoprotein (Env)-dependent fusion of viral membrane with the membrane of target cells expressing CD4 and an appropriate coreceptor. Cells transfected with the CCR5-2 plasmid failed to fuse with the reporter targets, whereas cells transfected with a CCR5-1 plasmid exhibited strong fusion activity with partner cells expressing Envs from either the macrophage-tropic strain, Ba-L, or the dual-tropic isolate, 89.6 (Fig. 3) (24) . The individuals were identified in two ways: 103 were identified as those individuals for whom samples were available that had risk scores in the top tenth percentile of all seronegative MACS participants. An additional 28 were tested because they had been previously reported to be transiently infected with HIV-1, suggesting inherent resistance (25); 6 of these individuals also had risk scores in the top tenth percentile. For reference, the distribution of risk for the entire seronegative MACS cohort followed until at least 1990 (n = 2430) is skewed markedly to the left with a median of 5 partners, 25th percentile of 16, and 90th percentile of 42 (Fig. 4A) Caucasian LTNPs (n = 85) and the rest of the HIV-1+ Caucasians (n = 529) was statistically significant (chi-square, 1 degree of freedom = 7.42, p = 0.006) ( Table 2 ). The MACS cohort of LTNPs has previously been matched with moderately rapid and rapid progressors by multiple epidemiologic criteria (see Materials and Methods) to form 56 sets of matched triplets, 48 of which had only Caucasian members (23) . The distribution of the eight possible genotype combinations for the Caucasian triplets is shown in Table 3 . Most members (106/ 144) were homozygous for the wild-type CCR5-1 allele. CCR5-2 heterozygous individuals were found in 28 of the 48 triplets. Their distribution in the three progression categories was: LTNPs, 17; moderately rapid progressors, 8; and rapid progressors, 13. Eleven triplets had two heterozygous members, and one triplet had three heterozygous members. Twelve triplets were biased in favor of a relationship of the heterozygous CCR5-2 genotype with slower progression (that is, triplets having only a nonprogressor member or both a moderate progressor and a nonprogressor member, but not a rapid progressor member, who are heterozygous for CCR5-2), and eight triplets were biased in favor of rapid progression (that is, triplets having only a rapid progressor member or both a moderate progressor and a rapid progressor member, but not a nonprogressor member, who are heterozygous for CCR5-2). Among the triplets with heterozygous members, differences in the observed and expected frequencies of CCR5 ( 11) .
The discovery of healthy adult blood donors homozygous for CCR5-2 suggests that a functional CCR5 allele is not essential for development. Furthermore, the absence of a significant difference between observed and expected numbers of CCR5-2 homozygotes in the populations tested suggests that normal CCR5 function is dispensable, perhaps the result of the extensive overlap of chemokine and leukocyte selectivity found within the family of CC chemokine receptors (1) . This is consistent with the absence of obvious health problems in the two exposeduninfected CCR5-2 homozygotes previously reported (10) . Additional studies will be needed to examine the role of CCR5-2 in diseases that occur after development and reproduction, particularly chronic inflammatory diseases such as atherosclerosis.
The factors that fixed CCR5-2 in the Caucasian population await elucidation; perhaps other microbial opportunists that could use wild-type CCR5-1 but not CCR5-2 for pathogenesis during the course of major ancestral epidemics were responsible. This concept has a parallel in the relationship between Plasmodium vivax, a causative agent of malaria, and expression on red cells of the Duffy antigen, another chemokine receptor subtype (35) (36) (37) . Indeed, it is believed that, under a process of gene inactivation for Duffy caused by the selective pressure of malaria, the majority of individuals descended from P. vivax-endemic areas now lack Duffy expression on their red cells and are resistant to vivax malaria. Although CCR5 acts as a susceptibility factor to HIV-1 infection in vivo, the resultant selective pressure is too recent (given the relatively recent emergence of HIV-1) in evolutionary time to account for fixation of CCR5-2 in the general population.
Our genotype data showing a similar frequency of heterozygous CCR5-2 for Caucasian random blood donors and for both HIV-1+ and exposed-uninfected Caucasians strongly suggest that CCR5-2 heterozygotes are equally susceptible to HIV-1 infection as are wild-type homozygotes. This agrees with the report of Dean et al. (12) (Fig. 4B) . It is also of interest that the other two exposed-seronegative CCR5-2 homozygotes were from the 22 exposed-seronegative MACS donors who were genotyped because they had been reported to be transiently viremic with HIV-1, suggesting innate resistance (25) .
Conversely (12) . Interestingly, they did not observe a significant difference in genotypic frequencies for cohorts of hemophiliacs segregated by rate of progression, which suggests that other factors can modulate the contribution of the CCR5-2 heterozygous genotype to the progression phenotype.
To understand these epidemiologic findings mechanistically, it will be important to correlate the frequency of CCR5-expressing cells and the level of CCR5 expression per cell both with viral replication in vitro and the rate of progression in infected patients, and to test whether these parameters differ in magnitude in CCR5-2 heterozygous versus wild-type homozygous individuals.
Taken together, the data suggest that the effect of gene dosage for wild-type CCR5 differs for initial infection versus clinical progression. Perhaps this is a consequence of differential expression of CCR5 in target cells in the mucosal barriers, where initial infection occurs, relative to lymphoid tissue that may be more important for amplification and spread of the virus. Detailed studies of CCR5 gene regulation and in vitro studies of viral replication in permissive cells from individuals homozygous for wild-type CCR5 and heterozygous for CCR5-2 are needed to clarify this finding.
Thus, the hypothesis that CCR5 is important for HIV-1 susceptibility and disease progression, which had as its origin the identification of HIV-1 coreceptor activity for CCR5 in vitro, has withstood a critical genetic test in populations of individuals having extremely polar clinical outcomes. The mutation in CCR5-2 causes disruption of the HIV-1 coreceptor activity and appears to confer high resistance to HIV-1, but only in homozygous individuals. This implies that other HIV-1 coreceptors are not sufficient for HIV-1 infection; whether they are necessary for HIV-1 infection or whether they affect the rate of disease progression requires further study. Although the relative rarity or absence of CCR5-2 homozygotes in the populations tested suggests that this mutation plays, at most, a minor role in checking the spread of the HIV-1 epidemic on a population level, the results also imply conversely that wild-type CCR5 may be an excellent target for the development of anti-HIV-1 drugs with broad clinical utility.
